Builds Upon the BOOST-2 Trial to Improve TBI Outcomes
Under the guidance of co-principal investigator, Lori Shutter, MD, the University of Pittsburgh is a coordinating center for the $32 million Brain Oxygen Optimization in Severe TBI, Phase 3 (BOOST-3) clinical trial, which aims to improve outcomes for severe traumatic brain injury patients. BOOST-3 is a multicenter trial that will monitor the partial pressure of oxygen in brain tissue, and apply interventions to prevent brain tissue hypoxia and improve neurologic outcome.
“It’s important to consider the long-term survival and health of patients with TBI,” says Dr. Shutter, who was co-PI of the trial’s second phase, BOOST- that was published in 2017. “This phase of the trial will show whether we can improve long-term outcome with this treatment strategy.”
The BOOST-3 trial builds upon its predecessor, BOOST-2, which showed that brain hypoxia burden was reduced in patients monitored and treated based on both the partial pressure of oxygen in brain tissue and intracranial pressure rather than only intracranial pressure. The second phase of the trial, BOOST-2, was published in Critical Care Medicine by Dr. Shutter and Ramon Diaz-Arrastia, MD, PhD, in 2017.
Dr. Shutter designed the BOOST-3 trial along with co-principal investigators William Barsan, MD, a professor of emergency medicine at Michigan Medicine; Ramon Diaz-Arrastia, MD, PhD, Director of the Traumatic Brain injury Clinical Research Center in the Perelman School of Medicine at the University of Pennsylvania; and Sharon Yeatts, PhD, associate professor of biostatistics at the Medical University of South Carolina.
Read more about the BOOST-3 clinical trial.
Lori Shutter, MD, is Vice Chair of Education in the Department of Critical Care Medicine, and Medical Director of the Neurovascular and the Neurotrauma ICUs at UPMC Presbyterian Hospital. She is a professor of Critical Care Medicine, Neurology and Neurosurgery.